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ABSTRACT
Objective: Statins have been shown to reduce the risk of major cardio-
vascular disease. We recognize that there is a major gap between the use of
statins in actual practice and treatment guidelines for dyslipidemia. Low
adherence to statins may have a signiﬁcant impact on clinical issues and
health-care costs. The objective is to evaluate the impact of low adherence
to statins on clinical issues and direct health-care costs.
Methods: A cohort of 55,134 patients newly treated with statins was
reconstructed from the Régie de l’Assurance Maladie du Québec and
Med-Echo databases. Subjects included were aged between 45 and 85,
initially free of cardiovascular disease, newly treated with statins between
1999 and 2002, and followed-up for a minimum of 3 years. Adherence to
statins was measured in terms of the proportion of days’ supply of medi-
cation dispensed over a deﬁned period, and categorized as 80% or
<80%. The adjusted odds ratio (OR) of cardiovascular events between the
two adherence groups was estimated using a polytomous logistic analysis.
The mean costs of direct health-care services were evaluated. A two-part
model was applied for hospitalization costs.
Results: The mean high adherence level to statins was around to 96%
during follow-up; and this value was at 42% for the low adherence level.
The patients with low adherence to statins were more likely to have
coronary artery disease (OR 1.07; 95% conﬁdence interval [CI], 1.01–
1.13), cerebrovascular disease (OR 1.13; 95% CI 1.03–1.25), and chronic
heart failure within 3-year period of follow-up (OR 1.13; 95% CI 1.01–
1.26). Low adherence to statins was also associated with an increased risk
of hospitalization by 4% (OR 1.04; 95% CI 1.01–1.09). Among patients
who were hospitalized, low adherence to statins was signiﬁcantly associ-
ated with increase of hospitalization costs by approximately $1060/patient
for a 3-year period.
Conclusion: Low adherence to statins was correlated with a higher risk of
cardiovascular disease, hospitalization rate, and hospitalization costs. An
increased level of adherence to statins agents should provide a better
health status for individuals and a net economic gain.
Keywords: adherence to treatment, health-care costs, statins.
Introduction
Cardiovascular diseases are responsible for the highest health-
care utilization costs in most industrialized countries [1–3].
Many risk factors are involved in the development of the disease
[2,4]. The lifetime risk of cardiovascular disease is 1.5 to 2 times
higher for people with elevated total cholesterol levels than for
those with normal lipid levels [4,5]. Dyslipidemia is a common
chronic condition and an important risk factor for cardiovascu-
lar disease in general. Because of the high prevalence, the costs
related to dyslipidemia are substantial. The ﬁnancial impact of
dyslipidemia stems not only from the treatment of cholesterol,
but also from the costs of managing the chronic diseases linked
with this condition.
Clinical trials have shown that decreased LDL-cholesterol
levels resulting from statin therapy can reduce cardiovascular
morbidity and mortality [6]. Clinical trials of primary prevention
have shown that statins reduce the incidence of coronary artery
disease by approximately 30% [7–10] and of stroke by 14% to
23% [11,12]. Statins could reach their full therapeutic potential
after 1 or 2 years of continuous treatment [13]. Despite this
evidence, statins are not used optimally, the efﬁcacy shown in
randomized clinical trials may therefore be irrelevant in real life
[14,15].
We recognize that there is a major gap between the use of
statins in actual practice and treatment guidelines for dyslipi-
demia [6]. Despite this evidence, statins are not used optimally,
and the efﬁcacy shown in randomized clinical trials may there-
fore be irrelevant in real life [14,16,17]. Nonadherence is likely
an important source of preventable cardiovascular morbidity and
mortality [18]. Nonadherence to cardioprotective medication has
been associated with a broad range of adverse outcomes such as
all-cause and cardiovascular mortality, cardiovascular hospital-
ization, and revascularization procedures in patients with coro-
nary artery disease [19]. Unfortunately, little is known about the
impact of medication nonadherence to statin agents in regards to
cardiovascular events, hospitalization, and health-care costs in a
real cardiovascular primary prevention setting. Our study evalu-
ates the risk of cardiovascular disease, hospitalization, and direct
health-care costs related to low adherence to statins in the
primary prevention of cardiovascular disease from the perspec-
tive of the health-care system in the province of Quebec, Canada.
Methods
Data Sources
The data were collected from the Régie de l’Assurance Maladie
du Québec (RAMQ) and Med-Echo databases, both of which
administer public health-care insurance programs in the province
of Québec, Canada. The Med-Echo database contains informa-
tion on acute care hospitalizations, such as date of admission,
length of stay, primary and up to 15 secondary diagnoses (Inter-
national Classiﬁcation of Diseases 9th revision [ICD-9] codes)
[20]. The RAMQ has four types of databases. The beneﬁciaries
database lists age, sex, social assistance status and, where rel-
evant, date of death of all registered people. The medical services
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ﬁle contains claims for all inpatient and ambulatory services and
includes information such as the date, nature and location of the
medical acts, diagnoses and procedure codes as well as the costs
of the acts and procedures. The diagnostic codes are classiﬁed
according to the ICD-9 [20]. All surgical procedure codes are
compliant with the Canadian classiﬁcation of diagnostic, thera-
peutic, and surgical procedures [21].
The admissibility database lists the periods of eligibility to the
RAMQ’s Public Prescription Drug Insurance Plan. The pharma-
ceutical database provides data on medications dispensed in
community drugstores such as the date of ﬁlling, name of the
drug, dose, quantity, dosage form, duration of therapy, and cost
of the drugs (insured and paid by patients). Even though the
RAMQ reimburses the costs of physician visits and medical
procedures for all Quebec residents, it reimburses the costs of
prescription drugs for a portion of the residents, estimated at
about 43% globally of the Quebec population [22]; but for more
than 94% of Quebec citizens aged 65 and older [23]. Individuals
covered by the RAMQ drug plan must pay an annual premium,
depending on net family income. Between 2002 and 2006, the
annual premium varied from $0 to $521 Canadian dollars. In
addition, each month they purchase prescription drugs, insured
persons pay a deductible and a coinsurance corresponding to
25% of the cost of drugs until they reach a maximum monthly
contribution which, between 2002 and 2006, varied from $16.66
to $71.42 Canadian dollars, regardless of the number of drugs
received.
All databases contain a unique identiﬁer, the individual’s
health insurance number, which serves as a link between them.
The pharmaceutical database has been evaluated and its validity
conﬁrmed [24]. Moreover, validity studies have been carried out
for several medical services claims contained in the Quebec
administrative databases [25–27].
Cohort Study
We selected all patients who initiated statins therapy with ator-
vastatin, ﬂuvastatin, lovastatin, pravastatin, simvastatin or rosu-
vastatin, between January 1, 1999 and June 30, 2002, and who
had not taken any statin in the 2 years before entry into the
cohort. Patients had to be between 45 and 85 years of age and
been covered for their drugs by the RAMQ for at least 2 years
before cohort entry. The date of the ﬁrst prescription for a statin
agent was deﬁned as the cohort entry date.
Furthermore, to be eligible, subjects had to be free of any
diagnosis of cardiovascular disease as demonstrated by the
absence of a vascular diagnosis or vascular medical procedure in
the 5 years before entering the cohort and no vascular drug
marker in the 2 years before the cohort entry date. Patients had
to be free of any of the following: 1) a diagnosis of myocardial
infarction or angina (ICD-9 codes 410–414), a related medical
procedure or drug marker; 2) a diagnosis of cerebrovascular
disease: diagnosis (430–438) or related medical procedure; 3) a
diagnosis of peripheral vascular disease (440–446) or related
medical procedure; 4) a diagnosis of chronic heart failure
(398.91, 402.01, 402.11, 402.91, 428.0, 428.1, and 428.9) or
the use of furosemide with digoxin, angiotensin-converting
enzyme (ACE) inhibitors, spironolactone, or b-blockers; 5) a
diagnosis of arrhythmia (426–427), a medical procedure involv-
ing a pacemaker or the use of drugs for cardiac arrhythmias; and
6) valvular heart disease (393–398). The RAMQ drug database
was also used to exclude patients who received other medications
such as antiplatelets (excluding low doses of aspirin) or antico-
agulants during the 2 years preceding the cohort entry.
Subjects were followed from the date of issuance of the ﬁrst
prescription of a statin until they lost their RAMQ drug insur-
ance coverage, admission to long-term care facility, death, or
until the end of the study period (June 30, 2005). The analyses
were performed for a 3-year follow-up period and all patients not
followed for this period of time were excluded.
Outcome Measures
Major cardiovascular events were deﬁned as follows: 1) coronary
artery disease was deﬁned by: a diagnosis of myocardial infarc-
tion or angina (ICD-9 codes 410–414), a vascular procedure
(coronary artery bypass grafting, angiography, angioplasty,
stent), or use of oral nitrate; 2) cerebrovascular disease was
deﬁned as an intracerebral hemorrhage (ICD-9 431), other and
unspeciﬁed intracerebral hemorrhage (432), occlusion and steno-
sis of precerebral arteries (433), occlusion of cerebral arteries
(434), acute but ill-deﬁned cerebrovascular disease (436), and
other ill-deﬁned cerebrovascular disease (432, 437); and 3)
chronic heart failure was deﬁned as (ICD-9 codes 398.91,
402.01, 402.11, 402.91, 428.0, 428.1, and 428.9) or the use of
furosemide with digoxin, ACE inhibitors, spironolactone, or
b-blockers.
Exposure Assessment
Pharmaceutical RAMQ database records were used to assess the
adherence level to statins, deﬁned as the extent to which a patient
ﬁlled his statin as prescribed according to the “medication pos-
session ratio” (MPR). The MPR corresponds to the total of days’
supply of medication dispensed in a period, including the switch-
ing for another agent, divided by the length of the follow-up
period, i.e., 1095 days [28,29]. Because drugs dispensed in hos-
pitals are not recorded in pharmaceutical RAMQ database,
adherence was assumed to be 100% during the length of hospi-
talization if the patient had ﬁlled a prescription less than 2
months before admission. The supply of medication dispensed
before hospital admission was carried over to the postdischarge
period. If MPR exceeded 100%, it was truncated at 100%.
Adherence was measured after the 3-year follow-up period. The
MPR was dichotomized by setting the MPR threshold at 80%.
Patients under this level were considered to have low adherence.
This cutoff point was chosen because in statins clinical trials,
patients must be at least 80% adherent to their medication in
order for them to beneﬁt from a signiﬁcant decrease in choles-
terol level [30,31].
Cost Assignment and Prediction of Hospitalization
Direct costs were assigned in Canadian dollars ($) using the
RAMQ medical, Med-Echo, and pharmaceutical databases. The
costs were categorized as either costs for medical services, hos-
pitalization, or drug related. Data from the medical database
were used to estimate the direct medical costs by summing the
cost of medical visits, medical procedures, and the investigative
tests within the community setting. The pharmaceutical database
was also used to calculate the incurred drug costs by summing all
ambulatory prescription drug costs.
The Med-Echo database was used to determine whether a
patient was hospitalized during the period of analysis, and where
applicable, we estimated the total duration of hospitalization
during the period by summing the length of each hospitalization
in the period. The cost of hospitalization was calculated for each
person, by multiplying the total duration of hospitalization with
the mean daily cost of hospitalization in Quebec, which was at
$750 in 2005 according to the Quebec Health Ministry. This
amount includes nursing care, laboratory tests, drugs, laundry,
food, administration, and maintenance costs.
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All categories of costs were estimated based on all-cause costs
method and disease-related costs method. The all-cause costs
method sums all the expenditure incurred in the period of analy-
sis. Disease-related costs method estimates costs by restricting its
attention to expenditure (hospitalization, medical, and pharma-
ceutical) related to dyslipidemia or cardiovascular disease [32].
Covariates
Several covariates were considered as potential determinants of
cardiovascular events, hospitalization, and health-care costs. Age
groups, sex, and social assistance status were determined at the
cohort entry date from data in the individual’s ﬁle.
Comorbidities were deﬁned as follows: diabetes by ICD-9
code 250 or by the use of insulin or hypoglycemic agents; hyper-
tension by essential hypertension ICD-9 code 401 or by the use of
thiazides, ACE inhibitors without furosemide, calcium channel
blockers, or b-blockers without other markers of coronary artery
disease. These were identiﬁed in the year preceding the cohort
entry date and during the follow-up period. To evaluate the
overall health status, the modiﬁed patient’s Van Korff chronic
disease score was assessed in the year preceding the cohort entry
date and dichotomized based on the distribution. Scores were
weighted according to the number of different chronic diseases
under treatment [33]. Finally, the fact of being hospitalized in the
year preceding the cohort entry date and the mean number of
physician consultation per year were also identiﬁed as covariates
[34].
The occurrence of a coronary artery disease event, a cere-
brovascular event, chronic heart failure, or any other cardiovas-
cular events (peripheral artery disease, arrhythmia, valvular heart
disease, etc.) during follow-up were also considered in the mod-
elization of the risk of being hospitalized and health-care costs.
Statistical Analysis
The difference in demographic and clinical characteristics
between low and high adherence groups was analyzed with the c2
test. The adjusted odds ratio (OR) of cardiovascular events
between the two adherence groups was estimated using a poly-
tomous logistic analysis adjusted for all the covariates described
previously.
The nonadjusted mean costs of medical services, hospitaliza-
tion and drug-related between both adherence levels were evalu-
ated using t tests. For hospitalization costs, because a substantial
proportion of the study population was not hospitalized, a two-
part model was applied: the ﬁrst part estimated the probability of
being hospitalized; and the second part estimated the costs of
hospitalization among those who had been hospitalized using
multiple regression model (predicted conditional costs of hospi-
talization) [35–37]. In addition, to measure the impact of model
selection, we also used a gamma distribution based on the algo-
rithm proposed by Manning and Mullahy [38].
The hospitalization cost for each patient in the whole cohort
was deﬁned as unconditional hospitalization cost and was pre-
dicted by multiplying the estimated probability of being hospi-
talized with the predicted conditional costs of hospitalization.
The adjusted mean excess costs of hospitalization attributable
to low adherence of statins among patients who were hospital-
ized, and also for the whole cohort were estimated by the method
proposed by Aﬁﬁ et al. [39]. The mean from the differences of
individual costs between the low and high adherence groups
predicts the adjusted mean excess costs of hospitalization attrib-
utable to low adherence among patients who were hospitalized.
The adjusted mean excess costs among the whole cohort were
obtained by the same method and by multiplying these estimates
by the probability of being hospitalized.
The total costs of hospitalization were estimated by multiply-
ing predicted mean costs of hospitalization in the whole cohort
by the number of nonadherent and adherent patients, respec-
tively. The total excess costs of hospitalization attributable to low
adherence were estimated by multiplying the mean excess costs
of hospitalization between the two groups in the whole cohort
with the number of individuals in the low adherence group.
Finally, the total savings in costs of hospitalization attributable to
the high adherence group were estimated by multiplying the
mean excess costs of hospitalization between the two groups in
the whole cohort with the number of individuals in the high
adherence group.
To assess the impact of excluding the patients who died or
lost their drug insurance coverage within the 3-year period, we
ran a sensitivity analysis for a 1-year period of follow-up. In
addition, a sensitivity analysis was performed for the thresholds
of the adherence groups at 70% and 90%. We built conﬁdence
intervals (CI) and estimated the mean standard error by using the
bootstrap method with 1000 iterations [40]. All models were
adjusted for potential covariables and the signiﬁcance level was
set at 5%. All analyses were performed using the Statistical
Analysis System Software (version 9; SAS Institute, Cary, NC,
USA) and all tests were two-sided.
Ethical Considerations
No patient or physician identiﬁers were provided to the research-
ers; only scrambled identiﬁers were used throughout the study.
The Research and Ethics Committee of the University of Mont-
real approved the study.
Results
Demographic and Clinical Characteristics of Patients
Table 1 provides demographic and clinical characteristics of the
patients at the cohort entry date with respect to the adherence
level. A total of 61,359 patients were identiﬁed after applying the
inclusion and exclusion criteria. Of that, 1942 patients (3.2%)
were excluded because they died and 4283 patients (7.0%)
because they lost their RAMQ drug insurance coverage or have
an admission to a long-term care facility in the period of follow-
up. Among the cohort of 55,134 patients followed for at least 3
years, 48% had a low adherence level to statins. We did not
observe any major differences, deﬁned as more than 5%, between
the groups except for the diabetes and hypertension. The mean
adherence level was at 68%, the median at 82%, the ﬁrst inter-
quartile at 41%, and the 3-th interquartile at 99%, respectively.
The mean high adherence level to statins was around 96% (6%
SD) during follow-up; and this value was at 42% (26% SD) for
the low adherence level.
In total, 7326 patients have had a coronary artery disease,
2189 cerebrovascular events and 2171 a chronic heart failure.
We found a signiﬁcant difference between low adherence group
compared to high adherence group for the adjusted risk of coro-
nary artery disease (OR 1.07; 95% CI 1.01–1.13), cerebrovas-
cular events (OR 1.13; 95% CI 1.01–1.25), and chronic heart
failure (OR 1.13; 95% CI 1.01–1.15).
Distribution of Health-Care Costs by Adherence Level
Giving that we observed similar results for disease-related costs,
and that this method can underestimate the costs, we thus pro-
vided the costs using the all-cause costs method. The nonadjusted
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costs in low adherence group were at $1241 for medical costs,
$2496 for hospitalization costs, and $2506 for drug-related
costs; those estimates were at $1278, $2457, and $4847 in high
adherence group, respectively. For the entire cohort, the only
signiﬁcant difference between the two adherence groups was
observed in relation to drug-related costs. The nonadjusted dif-
ference was approximately $2300 among adherent patients com-
pared to nonadherent patients. Using a multiple linear regression,
this difference was decreased to $1900 after adjustment for all
the covariables.
Prediction of Hospitalization and Associated Costs
Among patients who were hospitalized, 73% of individuals
developed one or more cardiovascular condition in the low
adherence group as compared to 74% in the high adherence
group (P = 0.29). In the multivariate model (Table 2), low adher-
ence level was associated with an increased risk of hospitalization
compared to high adherence group (OR 1.04, 1.01–1.09). In
addition, age greater than 65 years, receiving social aid, devel-
oping a cardiovascular event, being diabetic, or having other
comorbidities increased the risk from 1.2- to 2.9-fold. Having
more than two cardiovascular events was also associated with an
increased probability of hospitalization by 8.0-fold.
Figure 1 shows the mean costs among hospitalized patients
comparing low adherence level (N = 7478) to high adherence level
(N = 8298). In the low adherence group, hospitalization amounts
to 60% of costs, followed by drug-related costs (23%) and
medical costs (17%); those values were respectively at 50%, 35%,
and 15% in the high adherence group. The mean length of
hospitalization for subjects in the low adherence category was
11.8 days compared to 11.3 days for the high adherence category.
Among hospitalized patients, the mean cost of hospitalization in
the low adherence group was associated with an increasing of
$1057 when compared to the high adherence group (Table 3).
Older age, receiving social aid, developing a cardiovascular event,
being diabetic, or the presence of other comorbidities were found
to be variables that signiﬁcantly increased the costs of hospital-
ization from $844 to $11,378. Similar results were obtained using
the gamma model with a log link function (data not shown).
Table 1 Characteristics of patients at cohort entry
Low adherence <80% High adherence 80% P-value*
Number of subjects 26,585 28,549
Age (mean SD)† 62.5 10 63.5 9 <0.0001
Statins at entry date (%):
Atorvastatin 61.5 61.9 <0.0001
Fluvastatin 3.6 3.0
Lovastatin 1.4 0.9
Pravastatin 16.5 17.1
Simvastatin 17.0 17.1
Mean equivalent dose of 20 mg of simvastatin 15.1 7.9 mg 14.7 7.4 mg <0.0001
Male 40% 39% 0.002
Social aid† (yes/no) 16% 18% <0.0001
Diabetes‡ (yes/no) 27% 35% <0.0001
Hypertension‡ (yes/no) 54% 67% <0.0001
Prior hospitalization§ (yes/no) 12% 13% 0.16
Chronic disease score§ (4) 6% 8% <0.0001
*t Tests for the continuous variables and c2 tests for the categorical variables.
†At treatment initiation.
‡ICD-9 or pharmacologic treatment in the year preceding the cohort entry and during follow-up.
§In the year before cohort entry date.
ICD-9, International Classiﬁcation of Diseases 9th Revision.
Table 2 Factors associated with the probability of being hospitalized over a 3-year period
Crude OR (95% CI) Adjusted OR (95% CI)
Low adherence group vs. high adherence group* 0.96 (0.92–0.99) 1.04 (1.01–1.09)
Age† < 65 Reference Reference
75 > Age 65 1.50 (1.45–1.57) 1.45 (1.38–1.52)
85 > Age 75 2.17 (2.04–2.32) 1.92 (1.79–2.07)
Male 1.04 (0.99–1.08) 1.02 (0.98–1.06)
Social aid (yes/no)† 1.02 (0.97–1.07) 1.24 (1.17–1.31)
Coronary artery disease‡ (yes/no) 2.16 (2.03–2.29) 2.13 (2.01–2.27)
Cerebrovascular events‡ (yes/no) 2.68 (2.40–2.99) 2.46 (2.20–2.75)
Chronic heart failure‡ (yes/no) 2.48 (2.17–2.83) 2.12 (1.85–2.42)
Having other cardiovascular events‡ (yes/no) 3.05 (2.89–3.22) 2.93 (2.78–3.10)
Having two cardiovascular events‡ (yes/no) 8.84 (7.48–10.1) 8.01 (7.02–9.15)
Diabetes§ (yes/no) 1.40 (1.35–1.46) 1.22 (1.16–1.27)
Hypertension§ (yes/no) 1.40 (1.34–1.45) 1.02 (0.98–1.06)
Prior hospitalization|| (yes/no) 1.68 (1.59–1.77) 1.58 (1.49–1.67)
Chronic disease score|| (4 vs. <4) 1.81 (1.70–1.94) 1.67 (1.56–1.80)
*Low adherence <80% and high adherence 80%.
†At treatment initiation.
‡ICD-9 or pharmacologic treatment during follow-up.
§ICD-9 or pharmacologic treatment in the year preceding the cohort entry and during follow-up.
||In the year before cohort entry date.
CI, conﬁdence interval; ICD-9, International Classiﬁcation of Diseases 9th Revision; OR, odds ratio.
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As shown in Table 4, the mean excess expenditure of pre-
dicted costs of hospitalization among hospitalized patients of
$1064 (95% CI $454 to $1644). For the whole cohort, a patient
with low adherence to statin agents is expected to cost on average
$359 (95% CI $181 to $532) more than a patient with a high
adherence level. Again, similar estimates were also observed
based on gamma regression ($1106 and $372; data not shown).
Expected Total Costs of Hospitalization
As shown in Figure 2, for 26,585 low adherent patients, the total
cost of hospitalization estimated for the follow-up period was
$71.0million (95%CI 63.1 M to 78.8 M), and the estimated total
excess costs of hospitalization attributable to low adherence
amounted to $9.5 million (95% CI 4.8 M to 14.1 M). On the
other hand, as shown in Figure 3, for 28,549 adherent patients,
the total cost of hospitalization estimated for the follow-up period
was $65.9 million (95% CI 62.6 M to 69.4 M), and the estimated
total savings in costs of hospitalization attributable to high adher-
ence amounted to $10.3 million (95% CI 5.2 M to 15.2).
Sensitivity Analysis
To assess the impact of excluding the patients who died or lost
their drug insurance coverage within the 3-year period, we ran a
sensitivity analysis for a 1-year period of follow-up. A total of
61,359 patients were identiﬁed after applying the inclusion and
exclusion criteria. Of that, only 575 patients (0.9%) were
excluded because they died and 1782 patients (2.9%) because
they lost their RAMQ drug insurance coverage or have an admis-
sion to a long-term care facility in the period of follow-up.
Finally, the cohort was at 59,000 patients followed for at least 1
year. The results at 1-year period of follow-up were similar with
those for 3-year period of follow-up, and can be found on
Tables A1 and A2 at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i1_Dragomir.asp.
The results of the sensitivity analyses concerning the thresh-
olds of adherence at 70% or 90% show consistent results, and
can be found on Table A3 at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH13i1_Dragomir.asp.
Discussion
Despite the evidence that statins reduce the risk of major cardio-
vascular disease and the widespread use of these medications in
dyslipidemic patients, we found that 48% of these newly treated
individuals had a low rate of adherence. The low adherence was
associated with an increasing risk of coronary artery disease,
cerebrovascular disease, and chronic heart failure by 7%, 13%,
and 13%, respectively; and also with an increased rate of hospi-
talization of 4%. Moreover, by using a nested case control
design, we previously reported that subjects who were high
adherent (80%) were less likely to present a ﬁrst coronary
artery disease (RR: 0.82; 95% CI 0.77–0.87) compared to a level
of <20% [41]; high adherence (80%) to statin agents was also
signiﬁcantly decreased the risk of cerebrovascular disease by
22% (RR: 0.74; 0.65–0.84) compared with low adherence
(<80%) [42]; and ﬁnally, high level of adherence to statins was
associated with a 19% reduction of chronic heart failure (RR:
0.81; 0.71–0.91) [43].
We showed that for patients who actually used hospitaliza-
tion services, a low level of adherence was signiﬁcantly associated
with increasing costs of hospitalization by approximately $1060
per person within a 3-year period of follow-up. The public health
impact of low adherence is substantial e.g. the total costs of
hospitalization among 28,549 adherent patients were $65.9 M
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10000
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Figure 1 Mean costs among hospitalized patients*. *P > 5%, t test for the
difference in mean costs (medical, hospitalization) between low and high adher-
ence groups; P < 0.0001 for drug-related costs.
Table 3 Adjusted model of predictors of costs of hospitalization among hospitalized patients (conditional costs)
Crude coefﬁcients* (95% CI) Adjusted coefﬁcients* (95% CI)
Intercept — 2,542 (1,726 to 3,358)
Low adherence group vs. high adherence group† 422 (-191 to 1,036) 1,057 (460 to 1,652)
Age‡ < 65 Reference Reference
75 > Age 65 291 (-364 to 947) 844 (128 to 1,561)
85 > Age 75 2,813 (1,824 to 3,792) 2,598 (1,587 to 3,608)
Male -196 (-822 to 430) -401 (-1,012 to 209)
Social aid (yes/no)‡ 3,078 (2,270 to 3,886) 2,795 (1,897 to 3,693)
Coronary artery event§ (yes/no) 300 (-562 to 1,163) 505 (-347 to 1,358)
Cerebrovascular events§ (yes/no) 6,006 (4,553 to 7,460) 6,045 (4,608 to 7,480)
Chronic heart failure§ (yes/no) 6,335 (4,555 to 8,114) 5,359 (3,596 to 7,122)
Having other cardiovascular events§ (yes/no) 3,770 (3,038 to 4,503) 3,831 (3,105 to 4,557)
Having 2 cardiovascular events§ (yes/no) 11,710 (10,562 to 12,859) 11,378 (10,237 to 12,518)
Diabetes|| (yes/no) 3,467 (2,831 to 4,102) 2,412 (1,778 to 3,047)
Hypertension|| (yes/no) 1,670 (1,027 to 2,315) -352 (-1,011 to 306)
Prior hospitalization¶ (yes/no) 3,419 (2,598 to 4,240) 2,304 (1,505 to 3,103)
Chronic disease score¶ (4) 9,124 (8,125 to 10,122) 8,409 (7,417 to 9,400)
*Canadian $.
†Low adherence <80% and high adherence 80%.
‡At treatment initiation.
§ICD-9 or pharmacologic treatment during follow-up.
||ICD-9 or pharmacologic treatment in the year preceding the cohort entry and during follow-up.
¶In the year before cohort entry date.
CI, conﬁdence interval; ICD-9, International Classiﬁcation of Diseases 9th Revision.
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compared to $71.0 M for 26,585 nonadherent patients translat-
ing into an excess cost of hospitalization attributable to low
adherence of $9.5 M. In addition, those estimates do not con-
sider the fact that several cardiovascular conditions may cause
long-term functional incapacity, and we expect that the indirect
cost component associated with low adherence would even be
higher. The results emphasize the importance of developing cost-
effective interventions to reduce the burden of low adherence to
statins.
To the best of our knowledge, only two studies have been
previously published which have ascertained the impact of adher-
ence to statins medication on health-care services utilization and
their associated costs. The conclusions reached by both studies
[44,45] are similar to ours, namely that a low adherence level is
associated with a more frequent use of health-care services and
consequently, with higher costs. These studies only considered a
1-year period of follow-up, which is relatively short and may not
reﬂect as well the longer-term effects of nonadherence. We believe
that a 3-year period is more appropriate to measure the conse-
quences of a chronic condition such as dyslipidemia. In addition,
these studies had several restrictions related to recruitment and
did not adjust for severity of dyslipidemia which makes it difﬁcult
to extrapolate their results to a more general dyslipidemic
population.
The current study attempted to overcome some methodologi-
cal problems. Because of the concern about the treatment for
Table 4 Predicted mean costs of hospitalization
Predicted mean costs of hospitalization
in hospitalized patients (95% CI*)
Predicted mean costs of hospitalization
for the whole cohort (95% CI)
Mean total costs ($) 8654 (8358 to 8944) 2478 (2386 to 2571)
Mean costs in high adherence group ($) 8150 (7745 to 8543) 2310 (2193 to 2431)
Mean costs in low adherence group ($) 9214 (8776 to 9696) 2669 (2527 to 2816)
Mean excess costs between two groups ($) 1064 (454 to 1644) 359 (181 to 532)
*95% CI based on bootstrap method.
In Canadian dollars.
CI, conﬁdence interval.
Figure 2 Total costs of hospitalization during
follow-up in the low adherence group*. * Based on
estimates in Table 4.
Figure 3 Total costs of hospitalization during
follow-up in the high adherence group*. *Based on
estimates in Table 4.
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selection bias, we only used incident users. As with all observa-
tional studies of the effects of medications, the potential for
confounding by indication should be carefully evaluated [46].
First, we could not control for all the patient characteristics that
may inﬂuence the choice of physician. But, we controlled for
cardiovascular risk factors and the development of cardiovascu-
lar conditions during follow-up by including relevant variables in
the regression model to further decrease the bias. The covariables
were the fact of having hypertension or being a diabetic patient,
or of developing a cardiovascular condition after the initiation of
a statin agent. Second, to assess this possible bias, we evaluated
the rate of changing to different doses of statin and found that
most patients (79%) remained with the same dose, the rate of
switching to other statins was only 15%, although the rate of
switching to another lipid lowering class was at 2.8%. Moreover,
to reduce the likehood of confounding by dose, we evaluated the
doses of the different statins compared to an equivalency in
lowering LDL-cholesterol levels; and found that the doses were
comparable among low adherents and high adherents.
Third, this study population was large and representative of
diverse socio-demographic characteristics. Nevertheless, residual
confounding effects because of incomplete or inaccurate mea-
surement of covariates or unmeasured confounders such as
smoking cannot be excluded. For instance, patients who do not
adhere may have other traits that contribute to worsened out-
comes, including factors such as depression, lower socioeco-
nomic status, and associated adverse health behaviors [47], but
we were able to adjust in part for these factors. The observed
relation between good adherence to placebo and mortality sup-
ports the importance of the healthy adherer effect, where adher-
ence to medication may be a marker of overall healthy behavior
[48]. On the other hand, recent population-based studies have
attempted to differentiate whether the medication beneﬁts are
linked to the drug’s effect or to the healthier lifestyles of healthy
adherer effect [49,50]. Based on the differential class effects of
drug adherence on long-term survival, it has been suggested that
adherence-related beneﬁts associated with evidence-based phar-
macotherapies are mediated by drug effects more so than by
healthy adherer behaviors [49,50]. Moreover, the results
observed at 1-year period of follow-up were similar with those
for 3-year period of follow-up, suggesting that a selection bias
of healthier cohort of patients is certainly not a major
confounder.
Our study had some other limitations. Firstly, the RAMQ
databases do not provide any detailed information on clinical
data and thus, do not permit adjustments for the clinical severity
of dyslipidemia. Secondly, we used prescription reﬁll patterns to
assess exposure and thus, we cannot ascertain whether the dis-
pensed medication was actually taken by the patient. Neverthe-
less, some data suggest a good correlation between pharmacy
dispensing records and cumulative drug exposure as well as gaps
in medication supply [51]. Thirdly, our cohort is quite close to a
Canadian cohort where we are comparing several provinces
based on cardiovascular risk factors among Canadian population
of patients using statin agents [52]; we examined whether the
variables age and socioeconomic status are confounding factors
and we found that they have not been confounding factors. We
also believe that the results are generalizable in communities with
similar access to health care.
Finally, the RAMQ databases do not provide information
regarding certain costs such as those from nursing home and
home care services or hospital-dispensed drugs which prevents us
from incorporating them in the present cost calculations. Conse-
quently, the direct costs associated with low adherence are most
probably underestimated.
Despite these limitations, administrative databases provide
many advantages, mainly the ability to identify a large popula-
tion of users of a certain type of medication in a timely, efﬁcient
manner, and also reﬂect use in a real-life setting. Furthermore, a
recently published systematic review reported that administrative
databases are particularly suited for the evaluation of drugs
intended for long-term therapy [53].
In summary, our study of drug utilization patterns in a Cana-
dian setting showed that a high adherence to statins was signiﬁ-
cantly beneﬁcial in reducing inherent health-care costs in the
context of primary prevention of cardiovascular disease. Adher-
ence to pharmacological therapy is a key factor in determining
the success of various therapeutic approaches. Therefore, greater
attention should be paid to cost-effective interventions to
improve adherence which in turn may result in improved patient
outcomes and quality of life. Although nonadherence to statins is
prevalent, our study indicates that better adherence to these
agents is associated with a risk reduction for cardiovascular
disease in a real-world setting. The assessment of medication
adherence should be incorporated into routine clinical practice.
Interventions in this area are essential so that the therapeutic
beneﬁts translate into clinical practice.
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